What is the share price of Metropolis Healthcare Ltd (METROPOLIS) today?
The share price of METROPOLIS as on 23rd June 2025 is ₹1701. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Metropolis Healthcare Ltd (METROPOLIS) share?
The past returns of Metropolis Healthcare Ltd (METROPOLIS) share are- Past 1 week: 1.48%
- Past 1 month: 6.36%
- Past 3 months: 6.55%
- Past 6 months: -15.86%
- Past 1 year: -12.15%
- Past 3 years: 20.19%
- Past 5 years: 17.25%
What are the peers or stocks similar to Metropolis Healthcare Ltd (METROPOLIS)?
The peers or stocks similar to Metropolis Healthcare Ltd (METROPOLIS) include:What is the market cap of Metropolis Healthcare Ltd (METROPOLIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Metropolis Healthcare Ltd (METROPOLIS) is ₹8811.50 Cr as of 23rd June 2025.What is the 52 week high and low of Metropolis Healthcare Ltd (METROPOLIS) share?
The 52-week high of Metropolis Healthcare Ltd (METROPOLIS) is ₹2318.30 and the 52-week low is ₹1315.What is the PE and PB ratio of Metropolis Healthcare Ltd (METROPOLIS) stock?
The P/E (price-to-earnings) ratio of Metropolis Healthcare Ltd (METROPOLIS) is 60.78. The P/B (price-to-book) ratio is 8.02.Which sector does Metropolis Healthcare Ltd (METROPOLIS) belong to?
Metropolis Healthcare Ltd (METROPOLIS) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Metropolis Healthcare Ltd (METROPOLIS) shares?
You can directly buy Metropolis Healthcare Ltd (METROPOLIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Metropolis Healthcare Ltd
METROPOLIS Share Price
METROPOLIS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
METROPOLIS Performance & Key Metrics
METROPOLIS Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
60.78 | 8.02 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
35.49 | 6.52 | 0.85% |
from 17 analysts
Price Upside
Earnings Growth
Rev. Growth
METROPOLIS Company Profile
Metropolis Healthcare is a medical laboratory operator
METROPOLIS Sentiment Analysis
METROPOLIS Sentiment Analysis
METROPOLIS Stock Summary · May 2025
Metropolis Healthcare Limited is poised for a promising fiscal year 2026, projecting a 12% revenue growth driven by increased patient volumes and improved realization rates. Despite facing challenges such as seasonal fluctuations and the integration of newly acquired entities, the company is strategically enhancing its B2C segment, particularly in Tier 3 markets, where robust growth is evident. Innovations in specialty testing and a focus on operational efficiency are expected to bolster margins, while the successful integration of acquisitions aims to unlock cost synergies and expand market reach. Management remains optimistic about navigating competitive pressures and capitalizing on emerging opportunities, particularly in the wellness segment, which is gaining traction among consumers.
METROPOLIS Stock Growth Drivers
METROPOLIS Stock Growth Drivers
7Strategic Acquisitions and Market Expansion
Metropolis Healthcare has successfully completed three strategic acquisitions: Core Diagnostics, Scientific Pathology, and Dr. Ahujas'
Growth in Patient and Test Volumes
In FY '25, Metropolis Healthcare reported a 6% year-on-year increase in patient volumes and a
METROPOLIS Stock Challenges
METROPOLIS Stock Challenges
6Revenue Declines and Margin Pressures
The company experienced lower-than-usual revenue in February due to seasonal weather impacts on diagnostic demand,
One-Time Expenses and Financial Impact
Reported EBITDA was negatively impacted by one-time expenses of approximately INR 21 crores related to
METROPOLIS Forecast
METROPOLIS Forecasts
Price
Revenue
Earnings
METROPOLIS Share Price Forecast
METROPOLIS Share Price Forecast
All values in ₹
All values in ₹
METROPOLIS Company Revenue Forecast
METROPOLIS Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
METROPOLIS Stock EPS (Earnings Per Share) Forecast
METROPOLIS Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
METROPOLIS
METROPOLIS
Income
Balance Sheet
Cash Flow
METROPOLIS Income Statement
METROPOLIS Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 570.31 | 654.93 | 769.39 | 864.98 | 1,010.04 | 1,261.96 | 1,163.43 | 1,216.83 | 1,346.32 | 1,346.31 | ||||||||||
Raw Materials | 135.10 | 145.90 | 173.51 | 204.14 | 252.16 | 276.02 | 253.26 | 242.57 | 1,028.21 | 1,028.21 | ||||||||||
Power & Fuel Cost | 9.12 | 9.99 | 11.00 | 12.49 | 12.00 | 14.73 | 14.43 | 16.20 | ||||||||||||
Employee Cost | 127.70 | 147.37 | 176.21 | 190.16 | 198.64 | 233.17 | 252.73 | 275.78 | ||||||||||||
Selling & Administrative Expenses | 101.29 | 90.92 | 106.87 | 165.77 | 185.28 | 311.76 | 289.77 | 307.81 | ||||||||||||
Operating & Other expenses | 18.01 | 74.51 | 91.07 | 71.76 | 60.12 | 44.68 | 44.67 | 77.42 | ||||||||||||
EBITDA | 179.09 | 186.24 | 210.73 | 220.66 | 301.84 | 381.60 | 308.57 | 297.05 | 318.11 | 318.10 | ||||||||||
Depreciation/Amortization | 17.23 | 19.02 | 20.07 | 39.27 | 45.94 | 63.22 | 89.22 | 94.47 | 108.68 | 108.68 | ||||||||||
PBIT | 161.86 | 167.22 | 190.66 | 181.39 | 255.90 | 318.38 | 219.35 | 202.58 | 209.43 | 209.42 | ||||||||||
Interest & Other Items | 1.94 | 3.54 | 4.12 | 12.65 | 11.56 | 25.02 | 31.85 | 27.89 | 18.57 | 18.57 | ||||||||||
PBT | 159.92 | 163.68 | 186.54 | 168.74 | 244.34 | 293.36 | 187.50 | 174.69 | 190.86 | 190.85 | ||||||||||
Taxes & Other Items | 58.26 | 59.45 | 66.40 | 41.41 | 61.22 | 79.16 | 44.62 | 46.87 | 45.89 | 45.88 | ||||||||||
Net Income | 101.66 | 104.23 | 120.14 | 127.33 | 183.12 | 214.20 | 142.88 | 127.82 | 144.97 | 144.97 | ||||||||||
EPS | 20.48 | 21.00 | 24.07 | 25.26 | 36.00 | 41.88 | 27.91 | 24.96 | 28.29 | 28.30 | ||||||||||
DPS | 10.07 | 0.00 | 13.26 | 8.00 | 8.00 | 8.00 | 8.00 | 4.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.49 | 0.00 | 0.55 | 0.32 | 0.22 | 0.19 | 0.29 | 0.16 | 0.00 | 0.00 |
METROPOLIS Company Updates
Investor Presentation
METROPOLIS Stock Peers
METROPOLIS Past Performance & Peer Comparison
METROPOLIS Past Performance & Peer Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Metropolis Healthcare Ltd | 60.78 | 8.02 | — |
Max Healthcare Institute Ltd | 107.54 | 13.76 | 0.13% |
Apollo Hospitals Enterprise Ltd | 69.68 | 13.76 | 0.40% |
Fortis Healthcare Ltd | 73.59 | 6.66 | 0.13% |
METROPOLIS Stock Price Comparison
Compare METROPOLIS with any stock or ETFMETROPOLIS Holdings
METROPOLIS Shareholdings
METROPOLIS Promoter Holdings Trend
METROPOLIS Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
METROPOLIS Institutional Holdings Trend
METROPOLIS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has decreased by 1.44%
METROPOLIS Shareholding Pattern
METROPOLIS Shareholding Pattern
METROPOLIS Shareholding History
METROPOLIS Shareholding History
Mutual Funds Invested in METROPOLIS
Mutual Funds Invested in METROPOLIS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Metropolis Healthcare Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.1002% | Percentage of the fund’s portfolio invested in the stock 0.36% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 55/67 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 3.0747% | Percentage of the fund’s portfolio invested in the stock 1.46% | Change in the portfolio weight of the stock over the last 3 months -0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/35 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.1851% | Percentage of the fund’s portfolio invested in the stock 0.31% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 106/251 (-13) |
Compare 3-month MF holding change on Screener
smallcases containing METROPOLIS stock
smallcases containing METROPOLIS stock
Looks like this stock is not in any smallcase yet.
METROPOLIS Events
METROPOLIS Events
METROPOLIS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
METROPOLIS Dividend Trend
No dividend trend available
METROPOLIS Upcoming Dividends
METROPOLIS Upcoming Dividends
No upcoming dividends are available
METROPOLIS Past Dividends
METROPOLIS Past Dividends
Cash Dividend
Ex DateEx DateNov 17, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Nov 17, 2023
Cash Dividend
Ex DateEx DateFeb 23, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Feb 23, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2022
Dividend/Share
₹8.00
Ex DateEx Date
Feb 21, 2022
Cash Dividend
Ex DateEx DateFeb 17, 2021
Dividend/Share
₹8.00
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateFeb 13, 2020
Dividend/Share
₹8.00
Ex DateEx Date
Feb 13, 2020
METROPOLIS Stock News & Opinions
METROPOLIS Stock News & Opinions
Dapic Metropolis Healthcare (formerly known as Metropolis Histoxpert Digital Services), a wholly owned subsidiary of Metropolis Healthcare, has completed the acquisition of entire business of Dr. Ahujas' Pathology & Imaging Centre (DAPIC - a partnership firm), Dr. Alok Ahuja and Dr. Alka Ahuja (collectively referred to as 'acquired business') as a going-concern, effective 23 May 2025, in accordance with the terms agreed under the Business Transfer Agreement. Following the completion of the acquisition, the operations of the acquired business are now being carried out under Dapic Metropolis Healthcare effective 23 May 2025. Powered by Capital Market - Live
Despite the dip in profit, revenue from operations rose 4.31% year-on-year (YoY) to Rs 345.29 crore for the quarter ended 31 March 2025. Profit before tax fell 28.67% to Rs 36.04 crore in Q4 FY25, compared to Rs 50.53 crore recorded in the same quarter last year. EBITDA increased by 5% YoY to Rs 84 crore, compared to Rs 80 crore in Q4 FY24. However, the EBITDA margin declined to 24.3% in Q4 FY25 from 25.5% in the same quarter last year. The company continued to achieve growth in both patient and test volumes, while strategically reducing its exposure to the low-margin institutional business. Strong B2C growth was driven by infrastructure expansion and a greater focus on wellness services. The B2B segment posted double-digit growth, supported by enhancements in service quality and partner engagement. The TruHealth and Specialty segments emerged as the fastest-growing areas, aligning with the company's strategic focus. TruHealth revenues rose 20% YoY and contributed 19% to total revenues in Q4 FY25. B2C revenue for the quarter grew 14% YoY, with Maharashtra registering a notable 19% YoY increase in this segment. The specialty diagnostics segment posted 11% YoY growth. For FY25, patient volume increased by 6% YoY, while test volume rose by 7%. Revenue per patient also saw robust 6% YoY growth, supported by scientific upselling and micro-market pricing strategies. B2C revenues grew 17% YoY in FY25 and 14% YoY in Q4 FY25, reflecting the company's investments in consumer experience and network expansion. B2B revenue increased 12% YoY in FY25 and 10% YoY in Q4 FY25, driven by enhanced service quality and partner engagement. TruHealth revenues grew 24% YoY in FY25, with a strong Q4 contribution of 19% to total revenue. The specialty diagnostics segment maintained momentum with 13% YoY growth in FY25. Revenue growth from Tier III cities stood at 18% in FY25. The company expanded its reach to over 750 towns, adding 29 new labs and 400 centers during the year, thereby strengthening last-mile access. On a full-year basis, the company's consolidated net profit rose 13.41% to Rs 144.97 crore, on a 10.22% increase in revenue to Rs 1,331.20 crore in FY25 over FY24. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, 'Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence. We are confident that our recent acquisitions ' Core Diagnostics, Scientific Pathology, and Dr. Ahuja's Pathology & Imaging Centre ' will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value. Surendran Chemmenkotil, chief executive officer, Metropolis Healthcare, said, 'FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendations'boosting TruHealth performance. As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve.' Meanwhile, the company's board has approved the re-appointment of Ameera Shah as chairperson and whole-time director of the company for a term of five consecutive years, commencing from 18 March 2026 to 17 March 2031 (both days inclusive), subject to the approval of the shareholders. Further, the board has also approved the appointment of Surendran Chemmenkotil, currently serving as chief executive officer, as an additional director designated as managing director of the company for a term of three consecutive years, commencing from 01 June 2025 to 31 May 2028, subject to shareholder approval. Furthermore, Surendran Chemmenkotil will step down from his position as chief executive officer with effect from the close of business hours on 31 May 2025. Metropolis Healthcare is a diagnostics company with a presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Powered by Capital Market - Live
Net profit of Metropolis Healthcare declined 19.97% to Rs 29.14 crore in the quarter ended March 2025 as against Rs 36.41 crore during the previous quarter ended March 2024. Sales rose 4.32% to Rs 345.29 crore in the quarter ended March 2025 as against Rs 331.00 crore during the previous quarter ended March 2024. For the full year,net profit rose 13.42% to Rs 144.97 crore in the year ended March 2025 as against Rs 127.82 crore during the previous year ended March 2024. Sales rose 10.23% to Rs 1331.20 crore in the year ended March 2025 as against Rs 1207.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales345.29331.00 4 1331.201207.71 10 OPM %18.0424.16 -22.7623.40 - PBDT64.6776.95 -16 299.53269.16 11 PBT36.0450.53 -29 190.85174.69 9 NP29.1436.41 -20 144.97127.82 13 Powered by Capital Market - Live
Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live
Metropolis Histoxpert Digital Services is a wholly owned subsidiary of Metropolis Healthcare. Dr. Ahujas' Pathology and Imaging Centre (DAPIC) operates two laboratories accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) and National Accreditation Board for Hospitals and Healthcare Providers (NABH) 11 patient service centres, and nine hospital-based centres. DAPIC offers a comprehensive range of pathology and soft radiology services, including ultrasound, ECG, and X-ray. In FY 2024-25, DAPIC recorded an estimated annual revenue of INR 11.5 crore (unaudited*), with pathology services contributing 73% and radiology services 27%. With 80 percent of its revenue coming from walk-in patients, the chain has built a strong B2C presence, making it a valuable addition to Metropolis' growing network in North India,' the company said in a statement. Under the agreement, Metropolis Histoxpert Digital Services will acquire 100% ownership of DAPIC in an all-cash deal valued at Rs 35.01 crore. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business post-acquisition. Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said: Dr. Ahujas' Pathology & Imaging Centre has established a strong reputation for high-quality B2C services, scientific excellence, and patient trust, making it an ideal addition to Metropolis' growth strategy. Together with the acquisition of Core Diagnostics, a leader in oncology testing, Scientific Pathology, the dominant chain in Agra, and now DAPIC, the leading diagnostic chain in Dehradun, we are further strengthening our 'String of Pearls' strategy'aimed at building a robust and regionally diverse diagnostic network across North India. These strategic moves have expanded the North India contribution to our overall revenues from 8% to an estimated 14'15%. Building on this momentum, we aim to accelerate our expansion across Uttar Pradesh and Uttarakhand'two high-growth markets with significant potential.' In an exchange filing made on Saturday, Metropolis Healthcare announced its operational updates for the quarter ended on 31 March 2025. The company's consolidated revenue in Q4 FY25 grew by approx. 10% on a year-on-year (Y-o-Y) basis. Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits. The B2C revenues grew at approximately 14% on a Y-o-Y basis on account of consumer experience and expansion of service network. The operational EBITDA for the current quarter has grown marginally lower due to higher material costs and reduced revenue growth. Reported EBIDTA is lower due to one-time costs including acquisition costs for Core Diagnostics & Scientific Pathology and lower margin from Core Diagnostics. The company is debt free & has cash reserves of approximately Rs 112 crore, post paying towards acquisition amounting to Rs 130 crore as on 31 March 2025. Metropolis Healthcare is India's second largest diagnostic chain. The company's extensive footprint spans 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,300 service centres, and over 10,000 touchpoints. The scrip declined 3.04% to currently trade at Rs 1503.05 on the BSE. Powered by Capital Market - Live
Metropolis Healthcare announced that its wholly owned subsidiary, Metropolis Histoxpert Digital Services, has entered into a business transfer agreement to acquire Dehradun's leading diagnostic chain - Dr. Ahujas' Pathology and Imaging Centre (DAPIC). Under the agreement, Metropolis' wholly owned subsidiary Metropolis Histoxpert Digital Services, will acquire 100% ownership of DAPIC in an all-cash deal valued at INR 35.01 crores. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business post acquisition. Powered by Capital Market - Live
Metropolis Healthcare has granted 18,000 RSUs under the Metropolis - Restrictive Stock Unit Plan, 2020 to the eligible employee(s) of the Company on 17 March 2025. Powered by Capital Market - Live
Revenue from operations grew 10.9% YoY to Rs 322.77 crore in the quarter ended 31 December 2024. Profit before tax jumped 14.9% to Rs 42.34 crore in Q3 FY25, compared to Rs 36.85 crore recorded in the same quarter last year. EBITDA stood at Rs 72 crore, registering the growth of 9.4% as compared with Rs 66 crore posted in the corresponding quarter last year. The EBITDA margin slightly decreased to 22.20% in Q3 FY25, down from 22.50% in Q3 FY24. The company reported strong B2C revenue growth of 15% year-over-year (YoY) in Q3FY25. Patient volume increased by 5%, while revenue per patient (RPP) saw a robust 10% growth, driven by enhanced upselling and value delivery. Additionally, B2B revenue grew by 10% YoY in Q3FY25, marking consistent double-digit growth for the third consecutive quarter. TruHealth revenue grew by 25% YoY, with its contribution rising from 14% in Q3 FY24 to 17% in Q3 FY25. The company's specialty revenue increased by 13% YoY, driven by a focus on specialized, non-seasonal tests. On nine-month basis, the company's consolidated net profit jumped 26.7% to Rs 115.83 crore in 9M FY25, compared to Rs 91.41 crore in 9M FY24. Revenue from operations rose 12.5% YoY to Rs 985.91 crore in 9M FY25. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, 'The diagnostics industry is undergoing a paradigm shift towards personalized medicine, genomics-driven testing, and preventive healthcare, fueled by advancements in molecular diagnostics, AI, and nextgeneration sequencing. At Metropolis, we remain at the forefront of this transformation, leveraging deep scientific expertise and consumer insights to drive innovation and expand access to cutting-edge diagnostics. Our strategic acquisition of Core Diagnostics is a pivotal step in this direction, strengthening our oncology and molecular diagnostics portfolio and reinforcing our commitment to becoming India's leading cancer testing provider. As part of our long-term strategy, we are expanding our presence in North India through a'string of pearls' approach, focusing on acquiring high-performing B2C businesses that are leaders in their cities, with strong EBITDA, ROCE, and cash flows. This strategy will enhance our capabilities and deepen our footprint in the region, driving long-term value creation and solidifying Metropolis' leadership in the evolving diagnostics landscape. Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, 'We have achieved double-digit growth for the third consecutive quarter, despite a traditionally challenging Q3 with lower illness-driven demand. This success stems from our focus on key segments, TruHealth and specialty, and our efforts to drive regional growth through targeted micro-marketing strategies and deeper market penetration. Through TruHealth' packages, we have been able to enhance the customer experience by integrating home-based ECG services, vital checks, and consultations. Additionally, the introduction of AI-powered MetAdvisor recommendation engine further personalises care by analyzing historical data and test combinations. With strong partnerships and an expanding network, we remain committed to addressing regional healthcare needs and driving sustainable growth. Our continued investments in technology and service excellence will deliver lasting value to customers and stakeholders. Meanwhile, the company's board has approved the appointment of Sameer Patel as chief financial officer and key managerial personnel of the company effective from 10 February 2025. This appointment will relieve Aditya Shinde from the additional role of Interim chief financial officer and key managerial personnel of the company effective from the close business hours of 09 February 2025. Aditya Shinde will continue to serve as Finance Controller. Metropolis Healthcare is a diagnostics company, with presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Powered by Capital Market - Live
Net profit of Metropolis Healthcare rose 15.46% to Rs 31.36 crore in the quarter ended December 2024 as against Rs 27.16 crore during the previous quarter ended December 2023. Sales rose 10.87% to Rs 322.77 crore in the quarter ended December 2024 as against Rs 291.12 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales322.77291.12 11 OPM %22.3122.27 - PBDT70.0361.85 13 PBT42.3436.85 15 NP31.3627.16 15 Powered by Capital Market - Live
Metropolis Healthcare has allotted Sameer Patel as Chief Financial Officer and Key Managerial Personnel of the Company effective from 10 February 2025. This appointment will relieve Aditya Shinde from the additional role of Interim Chief Financial Officer and Key Managerial Personnel of the Company effective from the close business hours of 09 February 2025. Aditya Shinde will continue to serve as Finance Controller.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.6%, vs industry avg of 10.01%
Over the last 5 years, market share decreased from 2.1% to 1.91%
Over the last 5 years, net income has grown at a yearly rate of 1.25%, vs industry avg of 42.91%